<DOC>
	<DOCNO>NCT00730964</DOCNO>
	<brief_summary>This prospective surveillance trial gather safety information Optison use routine practice .</brief_summary>
	<brief_title>A Prospective Surveillance Trial Evaluate Safety Optison Clinical Practice .</brief_title>
	<detailed_description />
	<criteria>The subject 18 year old . The subject schedule Optisonenhanced echocardiography exam . The subject provide sign date informed consent . Known hypersensitivity perflutren , blood , blood product albumin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Surveillance</keyword>
	<keyword>Optison</keyword>
	<keyword>Perflutren</keyword>
	<keyword>Echocardiography</keyword>
	<keyword>Subjects receive Optison enhance echocardiography</keyword>
</DOC>